FDA’s July 2026 review found that the limited ulcerative-colitis evidence could not establish BPC-157 effectiveness. The randomized report it examined involved rectal enemas and lacked important methodological details; it does not validate injected products for tendon or injury recovery.[1]
- The cited review was directed at proposed ulcerative-colitis uses and does not establish a global absence of human exposure.
- This is a pre-decisional Pharmacy Compounding Advisory Committee briefing for a July 2026 meeting; FDA states it will not issue a final determination until advisory-committee input is considered.
- The nominations for BPC-157 were withdrawn by their nominators; FDA is evaluating both BPC-157 free base and BPC-157 acetate on its own initiative because nominators gave inconsistent information about which form was proposed.
Inspection history
Clinical review: not reviewed by a qualified clinician.
· Independently inspected the listed passages; replaced or qualified inherited assertions. No qualified clinical review has occurred.
· Reopened the FDA briefing via a working PDF (curl User-Agent workaround after the automated request was blocked); reconfirmed the enema trial's denominators (53 randomized/46 completed) and the document's pre-decisional status. Text unchanged; limitations extended. No qualified clinical review.